Tumor News and Research

RSS

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens.

15 Feb 2013

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

Tumors are not factories for the mass production of identical cancer cells, but are, in reality, patchworks of cells with different patterns of gene mutations. In a new study, researchers at Dana-Farber Cancer Institute and the Broad Institute show, more fully than ever before, how these mutations shift and evolve over time in chronic lymphocytic leukemia (CLL) - providing a strobe-like look at the genetic past, present, and future of CLL tumors.

15 Feb 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Castle Biosciences launches MyUvealMelanoma website

Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common form of eye cancer. MyUvealMelanoma tells the story of this disease, its treatment and the importance of prognostic testing, through the experience of patients who recently faced this devastating diagnosis first-hand.

15 Feb 2013

Laparoscopic proctectomy stands up to open surgery

Laparoscopic surgery produces comparable results to open surgery for rectal cancer, show the findings of the first, large, randomized trial of the technique.

14 Feb 2013

Researcher to study ADAM12 gene in breast tumor initiating cells

A Kansas State University professor's research on breast cancer stem cells may help improve survival rates by preventing cancer recurrence and metastasis -- the major causes of death among breast cancer patients.

14 Feb 2013

Combination of Methotrexat and Tofacitinib shows promise against rheumatoid arthritis

Together with colleagues from the international rheumatic diseases research community, scientists of the Charité - Universitätsmedizin Berlin have presented a new therapy approach for the treatment of rheumatoid arthritis (RA), a chronic form of joint inflammation.

14 Feb 2013

IQGAP1 molecule can suppress growth of tumors in the liver

A molecule already implicated in a number of diverse cellular functions can suppress the growth of tumors in the liver, a Mayo Clinic Cancer Center study has found. Its name is IQGAP1, and when the molecule is active in the cells that surround a tumor cell, this "tumor microenvironment" becomes less hospitable to cancer growth. When the molecule is deficient, cancer thrives.

14 Feb 2013

FOXC2 vital to epithelial-mesenchymal transition in breast cancer

Researchers have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development.

14 Feb 2013

IAP antagonists may actually increase risk of bone tumors

Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone, according to researchers at Washington University School of Medicine in St. Louis.

14 Feb 2013

FDA grants orphan drug status to Lentigen’s LG631-CD34 for treatment of glioblastoma multiforme

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells for bone marrow protection in the treatment of glioblastoma multiforme.

14 Feb 2013

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

13 Feb 2013

Tivozanib overall survival results announced by AVEO and Astellas

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.

13 Feb 2013

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

13 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013